J&J expands its medical devices arm, buys private company Megadyne Medical Products
Ethicon Endo-Surgery has bought a private medical device company Megadyne Medical Products, Inc. for an unknown price.
Pharmaceuticals, Biotechnology and Life Sciences
Ethicon Endo-Surgery has bought a private medical device company Megadyne Medical Products, Inc. for an unknown price.
Xintela AB has reported positive results in its two main projects in regenerative medicine and cancer.
Flu, or influenza, is a very contagious, acute, viral respiratory infection. Influenza viruses vary in a high degree. The extent…
For the last year, Sanofi’s chief executive has made clear his quest for deals to help revive the fortunes of France’s biggest drugmaker.
The market is still waiting. Olivier Brandicourt’s failure to land two big biotech acquisitions he was chasing has led to growing impatience among some investors.
Bristol-Myers Squibb said on Thursday that it won’t seek an accelerated approval for the combination of Opdivo plus Yervoy in first-line lung cancer in the U.S.
Avacta expects to license Affimer technology in 2017, and it says this year is very optimistic for its shareholders.
Abzena has made a deal with a San Diego-based biopharmaceutical company for Abzena’s novel site–specific ThioBridge antibody drug conjugate (ADC) linker technology, which links antibodies and other proteins to drugs. The $300 million worth agreement with the…
Seasonal Affective Disorder (SAD) is a type of depression that comes and goes with the seasons, typically starting in the late fall and early winter and going away during the spring and summer. Depressive episodes linked to the summer can occur, but are much less common than winter episodes of SAD.
French company Cerenis Therapeutics has seen some good things happen in the previous period in clinics by finalizing certain studies and getting FDA’s approval to kick some off. Also certain results showed progress and the company has reported solid cash position for the end of the year.
Japanese Ministry of Health, Labour and Welfare (MHLW) has granted priority review to Bayer Yakuhin for regorafenib in the second-line…